Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation and Remission (DEAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Understand and sign the informed consent form.~2. Have documented ulcerative colitis on the basis of usual diagnostic criteria including clinical symptoms and findings from endoscopy, radiology studies, and histology.~3. Have a Simple Clinical Colitis Activity Index (SCCAI)55 score below 3 with no category value greater than 1 (Table 5).~4. Three or fewer bowel movements per 24 hours at the time of enrollment.~5. No visible blood in their bowel movements in the three days prior to enrollment.~6. Have either been on a stable dose of mesalamine medication (oral, rectal or a combination of oral and rectal, including sulfasalazine) or on no mesalamine medications for at least 4 weeks prior to enrollment.~7. Have been on either a stable dose of azathioprine, 6-mercaptopurine, or methotrexate or on none of these medications for at least 8 weeks prior to enrollment.~8. Have experienced at least one flare of ulcerative colitis in the 2 years prior to enrollment. A flare is defined as an increase in stool frequency, bleeding, urgency and/or abdominal discomfort sufficient to warrant a change in medication dose or addition of a new medication.~9. Most recently measured serum creatinine level in the preceding year less than 1.5 mg/dL.~Exclusion Criteria:~1. Age less than 18~2. Inability to speak and read English~3. Presence of an ostomy or prior total or subtotal colectomy~4. Current corticosteroid use or use within the two weeks prior to enrollment~5. Remission for less than 4 weeks prior to enrollment~6. Previous intolerance to mesalamine at doses greater than the current dose.~7. Use of rectally administered mesalamine or steroids within the 2 weeks prior to enrollment.~8. Currently taking more than 3.0 gm/day of mesalamine (oral or rectal). If on oral and rectal mesalamine, the combined dose is more than 3.0 gm/day.~9. Use of anti-TNFα therapies within the 8 weeks prior to enrollment and/or intent to use anti-TNFα therapies as maintenance therapy in the coming 12 weeks.~10. Pregnant or breast feeding women.~11. Use of an experimental therapy for ulcerative colitis in the 8 weeks prior to enrollment.~12. Any condition that the investigator feels will make completion of the study unlikely.~13. Use of cyclosporine in the two weeks prior to enrollment.~14. Moderate or severe abdominal tenderness on examination at time of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Increase mesalamine dose by 2.4g/day (Type: EXPERIMENTAL): Increase dose of mesalamine by 2.4 gm per day
- Maintain mesalmine dose (Type: NO_INTERVENTION): Maintain current mesalamine dose at 2.4 g/day

Based on this trial design, predict the completion outcome and termination type (if applicable).